《药物微生物技术》

本书是《现代微生物技术丛书》中的一个分册．全书系统论述了药物微生物技术的概念、研究内容和具体的应用技术．在介绍和归纳药物微生物、微生物药物和药物微生物技术的概念和内容的基础上,详细论述了药源微生物和微生物药物的筛选技术以及药物发酵合成的优化和生产技术,概述了微生物技术在基因工程药物和疫苗中的应用,对次级代谢产物合成的基因工程改造(次级代谢工程)和药物微生物基因组技术等新方法进行了分析和讨论．本书在顾及药物微生物技术传统内容的同时,将更多的篇幅用于介绍和归纳各种新的技术方法和思维策略,     

从草分枝杆菌的医疗价值看微生物天然药物开发的前景

草分枝杆菌培养物可以替代卡介苗，用于治疗嗜喘，膀胱瘤，本文重点介绍草分枝杆菌Cr-1菌株培养液增强机体免疫机能和抗氧化，抗衰老，抗辐射等功能的理论基础和实践应用，展示了微生物天然药物的开发前景。     

寻找微生物基因组中适合高通量药物筛选靶点的功能未知基因

开发有新作用机制的抗生素迫在眉睫。刚发现青霉素时 ,几乎所有的金黄色链球菌都是药物敏感型 ;异烟肼和链霉素刚用来治疗结核病时 ,效果几乎 1 0 0 % ,但 90年代中期 ,几乎 90 %的金黄色链球菌和 50 %以上的结核分枝杆菌都耐药 ,耐多药菌株也日益普遍。现有抗生素的作用机制比较单一 ,是细菌产生耐药性的一个主要原因。解决日益严重的细菌耐药性、交叉耐药性、毒性和难以根除条件致病菌感染最有效的途径是开发新作用机制的抗生素。1 .微生物基因组及其功能未知基因中蕴涵了开发新型抗生素的大量有用靶点抗生素开发首先往往需要鉴定靶点。靶…     

从阿维菌素获得诺贝尔奖到中国创造

纵观世界历史,大国崛起无不伴随着科技的兴起和机制体制的突破。来自大自然的天然产物对于人类的健康起到非常重要的作用,从抗肿瘤明星分子紫杉醇到挽救了无数人生命的抗感染药物青霉素,从治疗代谢疾病到营养保健,都离不开天然产物。此外,还有大量天然产物资源没有被开发过。而随着阿维菌素的发现者Satoshiōmura教授和William C.Campbell博士,及青蒿素的发现者屠呦呦研究员因为这两种天然产物在治疗寄生虫感染病和疟疾上的应用而获得2015年诺贝尔生理与医学奖后,天然产物有望迎来其发展的第二个黄金时代。我国是世界工厂也是天然药物的资源大国,为了实现产业升级,弯道超车,实现大国崛起的中国梦,我国科学家在"十二五"期间围绕着天然产物的高产和创新两大主题开展了富有成效的合成生物学研究。阿维菌素是由阿维链霉菌产生的高效低毒生物杀虫剂,其原料产能占国际市场的100%。但我国原有生产菌株的单位发酵产量较低,高消耗、高污染、片面追求生产规模的粗放型发展模式已经成了阻碍低碳经济持续高速发展的瓶颈。如何从根本上解决问题,提高生产菌株的单位发酵产量和原料利用率,降低能耗和生产成本,减少环境污染,是促进我国从"发酵大国"向"发酵强国"转变的关键。本文以阿维菌素为例,综述其基础研究的技术发展,特别是中国科学院微生物研究所引入合成生物学技术,将阿维菌素的单位产量提高了1000倍,至9 g/L,在内蒙古新威远与阿维菌素产业联盟的公司应用,迫使默克公司全面退出阿维菌素历史舞台,从而引领产业迅速发展的过程,为我国其它天然产物生物制造品种的改良提供思路和方法。     

多糖-药物轭合物的研究与展望

多糖类物质作为赋形剂在药物制剂中已被广泛使用,多糖结构中包含了多种活性基团如羟基、羧基、氨基等,具有良好的亲水性、生物可降解性以及生物安全性,使其在聚合物-药物轭合物的构建中成为理想的载体材料.目前天然的多糖大分子及其衍生物作为药物载体的研究方兴未艾,以多糖为载体的聚合物-药物轭合物在定位或靶向给药、组织工程、生物黏附等领域也备受关注.本文以天然多糖-药物轭合物的研究现状为切入点,总结归纳了多糖-药物轭合物的设计与构建途径,介绍了其在药物传递中的应用,讨论并分析了多糖在轭合物体系中的角色和发挥的作用,对以多糖为载体的聚合物-药物轭合物发展的方向予以了讨论.     

期待的新化合物登场分子靶向药物并用正式化

住2008年的ASCO上西妥昔单抗（Cetuximab）的试验结果引人关注。还有一些像PARP抑制剂等在新等级上取得好成绩的化合物。分子靶向药物的并用尝试已经正式展开。     

源于微生物的海鞘天然产物

海洋动物是具有生物活性海洋天然产物的重要来源。海鞘中含有丰富的微生物类群,如细菌、放线菌、真菌和蓝细菌。越来越多的直接或间接证据表明,一些从海鞘中分离的天然产物并不是海鞘本身产生的,而是由其共生微生物产生的。本文对近些年来的海鞘天然产物的微生物来源的研究方法进行综述,包括可培养细菌的分离、不可培养细菌的粗提物检测、宏基因组学、全基因组测序等直接方法,以及化合物结构比对的间接方法。通过对海鞘-微生物共生体中天然产物生物合成来源的研究,不仅可以从根本上解决动物药源的问题,而且可为研究海鞘与微生物共生关系提供有力证据。     

合成生物学助力天然产物的高效合成及创新发现

天然产物是候选药物以及药物先导化合物的重要来源,但传统的天然产物生产方式及新天然产物发现的速度和数量日益无法满足社会的巨大需求.随着合成生物学各方面技术的发展,合成生物学在天然产物高产和发现两个领域上的新策略、新方法、新应用应运而生,尤其在复杂天然产物的高效生物全合成、天然产物复杂前体结构的化学半合成、沉默天然产物的高...     

国内外从海洋微生物-开发新型药物的研究概况

本文根据国内外文献资料报道,综述了海洋微生物所产生的活性物质的特性及其药用价值,并阐述了国内外目前对海洋微生物资源的研究开发和发展展望。     

从典型硝化细菌到全程氨氧化微生物：发现及研究进展

生物硝化过程在全球氮循环中起关键性作用,被认为由氨氮氧化成亚硝酸盐和亚硝酸盐氧化成硝酸盐两个步骤组成,分别由氨氧化微生物(Ammonia oxidizing microorganisms,AOM)和硝化细菌(Nitrite oxidizing bacteria,NOB)催化完成。AOM包括氨氧化细菌(Ammonia oxidizing bacteria,AOB)和氨氧化古菌(Ammonia oxidizing archaea,AOA),AOB与AOA分布广泛,两者的相对丰度和氨氮浓度密切相关。2015年底,3个硝化螺菌属(Nitrospira)谱系Ⅱ的NOB被证实含有AOM的特征功能酶,包括氨单加氧酶(AMO)和羟胺脱氢酶(HAO),并证明NOB同时具有氨氧化和亚硝酸盐氧化的能力,命名为全程氨氧化微生物(Complete ammonia oxidizer,Comammox)。根据AMO的α亚基基因amoA的相似性将Comammox分为两大分支clade A和clade B。它们广泛分布于自然环境和人工系统,包括土壤(稻田、森林)、淡水(湿地、河流、湖泊沉积物、蓄水层)、污水处理厂和自来水厂等。本文综述了Comammox的发现及其最新的研究进展,并展望了Comammox作为氮循环关键功能菌群的研究方向和应用前景。     

宏基因组克隆--微生物活性物质筛选的新途径

在现有技术条件下自然界存在的微生物95％以上未能培养,采用传统的分离培养筛选的途径寻找新的微生物生物活性物质受到局限;宏基因组是特定小生境中全部微小生物遗传物质的总和,直接抽提环境样品中的总DNA,利用适宜的载体克隆到替代宿主细胞中构建宏基因组文库,通过外源基因赋予宿主细胞的新性状或基于某些已知DNA序列筛选,寻找新的生物活性物质或基因,极大地扩展了微生物资源的利用空间,增加了获得新的生物活性物质的机会。     

Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs

Drug repositioning (also referred to as drug repurposing), the process of finding new uses of existing drugs, has been gaining popularity in recent years. The availability of several established clinical drug libraries and rapid advances in disease biology, genomics and bioinformatics has accelerated the pace of both activity-based and in silico drug repositioning. Drug repositioning has attracted particular attention from the communities engaged in anticancer drug discovery due to the combination of great demand for new anticancer drugs and the availability of a wide variety of cell- and target-based screening assays. With the successful clinical introduction of a number of non-cancer drugs for cancer treatment, drug repositioning now became a powerful alternative strategy to discover and develop novel anticancer drug candidates from the existing drug space. In this review, recent successful examples of drug repositioning for anticancer drug discovery from non-cancer drugs will be discussed.     

A New Modeling Approach to the Effect of Antimicrobial Agents on Heterogeneous Microbial Populations

We develop a mathematical framework to model the dynamics of the effect of antimicrobial agents on heterogeneous microbial populations of distributed antimicrobial resistance. Our framework uses the concept of cumulants of a distribution. Simplifications that result in easily usable approximation tools are presented. A case study on experimental data exemplifies shortcomings of standard methods and the usefulness of the proposed approach. Suggestions for future development are made. Author to whom all correspondence should be addressed     

A Novel Approach for Bioremediation of a Coastal Marine Wastewater Effluent Based on Artificial Microbial Mats

A novel alternative for wastewater effluent bioremediation was developed using constructed microbial mats on low-density polyester. This biotechnology showed high removal efficiencies for nitrogen and phosphorous in a short retention time (48 h): 94% for orthophosphate (7.78 g m³ d⁻¹), 79% for ammonium (11.30 g m⁻³ d⁻¹), 78% for nitrite (7.46 g m⁻³ d⁻¹), and 83% for nitrate (8.55 g m⁻³ d⁻¹). The microbial mats were dominated by Cyanobacteria genera such as Chroococcus sp., Lyngbya sp., and bacteria of the subclass Proteobacteria representative of the Eubacteria Domain. Nitzschia sp. was the dominant Eukaryote Domain. Various N and P substrates in the wastewater permit the growth of self-forming and self-sustaining bacterial, microalgal, and cyanobacterial communities on a polyester support. The result is the continuous, self-sufficient growth of microbial mats. This is an innovative, economical, and environmentally safe alternative for the treatment of wastewater effluents in coastal marine environments.     

宏蛋白质组学:研究微生物群落的一种新策略

宏蛋白质组学是一种运用蛋白质组技术对特定微生物群落所产生的全部蛋白质进行大规模研究与分析的新技术。简要概述宏蛋白组学的产生、研究策略及其应用情况,并对其应用前景进行展望。     

Developing a Novel Approach of rpoB Gene as a Powerful Biomarker for the Environmental Microbial Diversity

Use of the rpoB gene (the encoding the β-subunit of RNA Polymerase gene), a potential alternative biomarker to the 16S rRNA gene, has been limited to environmental microbial investigation for a long time because of the lack of effective primers. Here we developed a novel rpoB gene-based approach using a newly designed primer pair and tested it in three different environmental water samples with the traditional library method. The results showed that our novel approach presented different microbial diversity patterns from the different environmental samples. Compared to previous rpoB gene based reports, the first retrieved groups in our approach included mainly α-Proteobacteria, δ-Proteobacteria, Planctomycetes, Verrucomicrobia, Firmicutes, Chlorofexi and Actinobacteria, which greatly expanded the potential ability of the rpoB gene approach for environmental surveys. Most importantly, the use of the traditional clone library approach with the novel rpoB gene primers greatly supplement the microbial diversity based on the 16S rRNA gene approach with the universal primer pair (27f and 1492r), at all phylum, class, order, family and genus levels, indicating a powerful complementary method and a potential alternative biomarker of the current popular NGS (next-generation sequences) technologies for the environmental microbial investigation.     

A New Approach for the Discovery of Antibiotics by Targeting Non-Multiplying Bacteria: A Novel Topical Antibiotic for Staphylococcal Infections

In a clinical infection, multiplying and non-multiplying bacteria co-exist. Antibiotics kill multiplying bacteria, but they are very inefficient at killing non-multipliers which leads to slow or partial death of the total target population of microbes in an infected tissue. This prolongs the duration of therapy, increases the emergence of resistance and so contributes to the short life span of antibiotics after they reach the market. Targeting non-multiplying bacteria from the onset of an antibiotic development program is a new concept. This paper describes the proof of principle for this concept, which has resulted in the development of the first antibiotic using this approach. The antibiotic, called HT61, is a small quinolone-derived compound with a molecular mass of about 400 Daltons, and is active against non-multiplying bacteria, including methicillin sensitive and resistant, as well as Panton-Valentine leukocidin-carrying Staphylococcus aureus. It also kills mupirocin resistant MRSA. The mechanism of action of the drug is depolarisation of the cell membrane and destruction of the cell wall. The speed of kill is within two hours. In comparison to the conventional antibiotics, HT61 kills non-multiplying cells more effectively, 6 logs versus less than one log for major marketed antibiotics. HT61 kills methicillin sensitive and resistant S. aureus in the murine skin bacterial colonization and infection models. No resistant phenotype was produced during 50 serial cultures over a one year period. The antibiotic caused no adverse affects after application to the skin of minipigs. Targeting non-multiplying bacteria using this method should be able to yield many new classes of antibiotic. These antibiotics may be able to reduce the rate of emergence of resistance, shorten the duration of therapy, and reduce relapse rates.     

Microbial Metabolism as an Evolutionary Response: The Cybernetic Approach to Modeling

ABSTRACT:?

The growth and metabolic capabilities of microorganisms depend on their interactions with the culture medium. Many media contain two or more key substrates, and an organism may have different preferences for the components. Microorganisms adjust their preferences according to the prevailing conditions so as to favor their own survival. Cybernetic modeling describes this evolutionary strategy by defining a goal that an organism tries to attain optimally at all times. The goal is often, but not always, maximization of growth, and it may require the cells to manipulate their metabolic processes in response to changing environmental conditions.

The cybernetic approach overcomes some of the limitations of metabolic control analysis (MCA), but it does not substitute MCA. Here we review the development of the cybernetic modeling of microbial metabolism, how it may be combined with MCA, and what improvements are needed to make it a viable technique for industrial fermentation processes.

IMTECH communication no.001/2001